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Introduction
In humans, estrogen influences many physiological
processes, which include not only reproduction, cardio-
vascular health, bone integrity, but also cognition and
behavior. Taking into consideration this widespread role
in human health it is not surprising that estrogen is
implicated in the development and progression of
numerous diseases, among which there are many types
of cancers (breast, ovarian, colorectal, prostate,
endometrial), osteoporosis, neurodegenerative diseases,
cardiovascular diseases, insulin resistance, lupus erythe-
matosus, lupus nephritis, endometriosis, obesity and as
it was shown in some recent studies- even occurrence of
graft-versus-host disease [1-10].
There are several different mechanisms through
which estrogens induce cellular changes. The most
important estrogens action is binding to its receptor
(ER). Estrogens diffuse into the cell and bind to ER
located in the nucleus. This complex binds to estrogen
response element sequences directly or indirectly
through protein-protein interactions with activator pro-
tein 1 (AP1) or SP1 sites in the promoter region of
estrogen-responsive genes. It results in recruitment of
coregulatory proteins (coactivators or corepressors) to
the promoter, increased or decreased mRNA levels and
associated protein production, and a physiological
response. There are evidence that estrogen can induce
cellular response through ER situated in plasma mem-
brane or through no-ER plasma membrane-associated
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estrogen binding proteins, resulting in increasing lev-
els of Ca2+ or NO and kinase activation [11].
ER exists in two main forms, ERα and ERβ,
encoded by separate genes, ESR1 and ERS2 respec-
tively, found in different chromosomes. The ESR1 is
located on chromosome 6q25.1 [47,72]. The ESR1
gene is large, encompassing 140kb of DNA, includes
8 exons, encodes a protein of 595 amino acids with a
molecular weight of about 66 kDa [14]. The first
intron of a gene, like the promoter, usually contains a
larger number of regulatory sequences than other
introns. Several sequence variations or single-
nucleotide polymorphisms (SNPs) in the ERα gene
have been identified and found to be associated with
either an increased or a decreased risk of various dis-
eases. The best characterized SNPs of ERS1 are the
PvuII and XbaI restriction site polymorphisms, both
located in the first intron (Figure 1). The polymor-
phisms, c454-397T→C and c454A→G, are 397 and
351 bp upstream of exon 2 and have been described
by the name of detecting restriction enzyme, PvuII or
XbaI, or their reference ID numbers, rs2234693 and
rs9340799, respectively [15,16]. Possible functional
mechanisms attributed to these polymorphisms
include a change of ERα gene expression by altering
the binding of transcription factors and influence on
alternative splicing of ERα gene.
In different studies, these polymorphisms have
been associated with several pathologic conditions
such as breast and prostate cancer, osteoporosis,
Alzheimer's disease and cardiovascular diseases
[1,2,5,9,17,18,19]. Results are still conflicting and
molecular mechanisms by which these polymorphisms
influence receptor activity are as yet unclear. PvuII and
XbaI RFLPs lie in an intronic and apparently nonfunc-
tional area of the gene and, as would be expected by
two polymorphisms separated by 50 base pairs, are in
strong linkage disequilibrium. 
In this study we aimed to evaluate distribution of
ERα PvuII and XbaI genotypes in population of Polish
postmenopausal women qualified to different proto-
cols of HRT.
Materials and methods
Patients. The study population comprised 64 white post-
menopausal women aged 45-65 years (mean 56.6) from the Lublin
region attending outpatient clinic. Women were considered post-
menopausal if they had no menstruation for at least 12 months with
no other obvious physiological or pathological cause or bilateral
oophorectomy. Body mass index of the participant ranged between
20.3 and 46.9 (mean 29.5). Eleven (17.2%) of women included
into the study were smokers. Exclusion criteria included cardio-
vascular, endocrinological, kidney, liver and any other serious dis-
orders. Women did not receive any hormonal treatment during the
last 1 year prior to study. 
Examination of polymorphisms. Genomic DNA was extracted
from the peripheral leukocytes using Genomic Prep Blood DNA
isolation kit (Amersham Biosciences, Piscataway, NJ, USA) fol-
lowing the manufacture's instruction. PvuII and XbaI polymor-
phisms were analyzed by polymerase chain reaction restriction
fragment lengths polymorphism (PCR-RFLP). A 1.372 kb DNA
fragment that contains the 2 polymorphic site was amplified
using forward and reverse primers 5'CTG CCA CCC TAT CTG
TAT CTT TTC CTA TTC TCC 3' and 5' TCT TTC TCT GCC
ACC CTG GCG TCG ATT ATC TGA 3'. PCR was performed
through 30 cycles by the following steps: denaturation at 64°C
for 60 s; annealing at 50°C for 60 s; and extension at 72°C for
90 s. PCR products were digested with the restriction endonu-
cleases PvuII and XbaI (Promega, Madison, WI, USA). Digest-
ed products analyzed on 2% agarose gel stained with ethidium
bromide. Heterozygous Pp genotype exhibited fragments 1372,
936 and 436 bp lengths and heterozygous Xx genotype exhibit-
ed fragments 1372, 982 and 390 bp lengths. Capital P or X rep-
resent the absence of restriction site while lower-case p or x
indicate the presence of restriction site.
Ethical issues. The study was approved by the Ethics Committee
of the Medical University of Lublin and written consent was given
by each participant. 
Statistics. Genotype distribution of the polymorphism was tested
for Hardy-Weiberg equilibrium by χ2. Linkage disequilibrium
resulting from the non-random association of the genotypes was
also assessed by χ2. A p-value less than 0.05 was considered sig-
nificant. Statistical analysis was performed with Statistica Statsoft
version 6.0 software. 
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Fig. 1. Structure of polymorphisms PvuII and XbaI in human
estrogen receptor α gene. Coding exons (E) are in boxes [14, mod-
ified].
Table 1. Frequency distribution of estrogen receptor α PvuII and
XbaI polymorphisms in studied female population
Results
In our studied population PvuII genotype was distrib-
uted as follows: PP 17.2% (n=11), Pp in 50% (n=32),
pp 32.8% (n=21). Frequency of XbaI genotype was:
XX 6.25% (n=4), Xx 34.4% (n=22), xx 59.4% (n=38).
The distribution of genotypes was in Hardy-Weinberg
equilibrium. As expected, linkage disequilibrium
between PvuII and XbaI polymorphisms was observed
(χ2=32.7, df=2, p< 0.000001). After combining the
two polymorphisms, four haplotypes with following
frequencies were recognized: PX 17.3%, px 47.4%, Px
24.4% and pX 10.9%. 
Table 1 shows the allele frequencies and heterozy-
gosity index for intron PvuII and XbaI polymorphisms
in our population. 
Discussion
As it is presented in Table 2, the distribution of PvuII
and XbaI polymorphisms was very similar to what was
previously reported in Caucasian populations of Euro-
pean ancestry and differed significantly from what was
observed in populations of Asiatic ancestry [20-26].
Asian populations showed an increased frequency of
the Px haplotype and a reduced frequency of the PX
haplotype with respect to Caucasian populations of
European ancestry, while in an African population
haplotype px was present at a lower frequency [27]. In
fact, a differential degree of linkage disequilibrium
among different ethnic populations may partly explain
previous discrepancies among ERα polymorphism
studies [28].
Haplotype pX was not observed in the majority of
studies, whereas haplotype Px was detected, albeit in a
low frequency. This frequency of haplotypes may
result from the disequilibrium which is not complete
and may be due to recombination or multiple muta-
tions which have occurred between or at these two
polymorphic sites.
There are a lot of evidences that ERα gene poly-
morphism influence many physiological processes in
humans, women in particular, as well as may be the
etiopathological factor of various diseases. 
The PX haplotype may be important in regulating
not only the onset, but also the end of high tissue
estrogen exposure during the lifetime of an individual.
One group of investigators has suggested that ERα
gene polymorphisms, in particular PvuII, may affect
the age of menopause [29,30]. In that study, the P
allele showed a dose-effect relationship with a 0.5 year
earlier onset of natural menopause per each copy of the
P allele and the risk of surgical menopause was higher,
by 2.4-fold, in women carrying the PP genotype as
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Table 2. Comparison of frequency of PvuII-XbaI haplotypes of the human estrogen receptor α gene in different ethnic groups
compared with pp homozygotes. Two other studies,
carried out in a Japanese and Dutch population, did not
replicate this finding [31,32].
The age of menarche was associated with the XbaI
and possibly the PvuII polymorphism of the ERα gene
in healthy adolescent Greek girls. In particular, menar-
che occurred 6 months later in girls with the AA geno-
type of the 351 A→C polymorphism than in girls with
AC or CC genotypes and tended to occur later in TT
homozygotes of the 397T→C polymorphism than in
TC and CC genotype carriers. XbaI XX homozygotes
or, in more general terms, subjects homozygous for the
PX haplotype seem to have a modest delay in the age
of menarche. The effects of PvuII are not as clear on
their own as the effects of XbaI. It may reflect the
strong linkage disequilibrium with XbaI and the PX
haplotype shows the strongest association with the age
of menarche. The biological pathway for XbaI and
PvuII that may affect the age of menarche is unknown.
Restriction sites of both polymorphisms are located in
the intron 1 of the ERα gene. Some introns contain
regulatory sequences such as enhancers, which means
binding sites for elements that regulate the level of
gene expression and thus also affect protein synthesis
[14,33,34]. The observed association may reflect link-
age disequilibrium with some other functional poly-
morphisms in the XbaI vicinity. Regardless of the
exact mechanism, if ERα gene polymorphisms can
alter the estrogenic biological activity at the cellular
level, this may influence the maturation of the hypo-
thalamic-pituitary-gonadal axis, which determines the
onset of menarche.
Salmén suggested that the PP genotype of the PvuII
polymorphism is a relatively estrogen-insensitive
genotype and that women with the p allele may bene-
fit more from the protective effect of the hormone
replacement therapy on fracture risk and atherosclerot-
ic severity than women with the pp genotype [25,35].
These results stress the importance of estrogen recep-
tor genotype and suggest that estrogen receptor has
potential to explain recent conflicting data on estrogen
replacement therapy and cardiovascular disease sus-
ceptibility in women.
Data regarding the influence of genetic variations
in ERα gene are contradictory. Numerous studies also
report an association between estrogen therapy and a
lower risk of cardiovascular disease. Polymorphisms
in ERα that link it to severity and risk of coronary
artery disease have been identified. In the Framingham
Heart Study, the ESR1 PvuII polymorphism is associ-
ated with an increased risk of myocardial infarction in
men and with blood pressure variation in men [7]. In
addition, the haplotype encompassing both ESR1
PvuII and XbaI polymorphisms is associated with an
increased risk of myocardial infarction and ischemic
heart disease in postmenopausal women in the Rotter-
dam Study [36]. Nordström demonstrated that the
presence of the p allele was associated with the
increased risk of aortic valve sclerosis [37]. ESR1
polymorphisms (pp genotype) are associated with
increased HDL cholesterol levels in postmenopausal
women with coronary disease in response to estrogen
therapy or HRT [38]. Moreover, XbaI polymorphism
(XX) was associated with an increasing risk of coro-
nary heart disease in postmenopausal women with
familial hypercholesterolemia [39]. ERα is expressed
in vascular endothelial cells, vascular smooth muscle
cells and cardiomyocytes [11]. ERα might be involved
in some elements of atherosclerotic plaques formation
which comes from observation that estradiol reduces
the histological complexity of plaques in the com-
pound gene-targeted animals. On the other hand, sev-
eral studies showed lack of association between ERα
gene polymorphism and increased risk of cardiovascu-
lar diseases in women after the menopause [7,40,41].
The PvuII polymorphism is associated with
increased breast cancer risk, as well as risk for other
disease in which estrogen is implicated. XX homozy-
gotes are protected from breast cancer and endometri-
al cancer [42,43]. A non-significant trend for protec-
tion against endometrial cancer has also been seen for
PP homozygotes [43]. It is unknown to what extent
these findings reflect differential cumulative exposure
to estrogens due to different estrogen levels, different
expression of ERs, different time duration of the estro-
gen exposure, or a combination of these factors. Part of
this protective effect may be mediated by a delayed
menarche and this may also be the case for XbaI XX
homozygotes [44]. A delayed menarche is a strong
protective factor against breast and endometrial cancer
and is related to reduced lifetime estrogen exposure of
the target tissues, as has been shown in several studies.
Studies in ERα knockout (αERKO) mice demon-
strated that ERα is required for normal mammary
gland development, because adult αERKO females
exhibit mammary glands lacking ductal development
end terminal end buds, resembling prepubertal stage
[45]. Loss of ERα in Neu/ErbB2 knock-in transgenic
mice resulted in lack of tumor development, while
these mice develop mammary glands tumors with long
latency period [46]. Another data suggesting function
ERs in tumor development and progression is that
mammary tumor incidence is minimized with loss of
ERα expression in the C3/T (AG) mouse model of
estrogen-promoted mammary tumorigenesis [47].
The ER is present in approximately two-thirds of
human ovarian tumors, not only of epithelial but also
stromal origin [11]. ERα plays role in the estrogenic
actions in the prostate which is supported by the obser-
vation that adult αERKO mice treated with DES do
not develop the prostatic squamous metaplasia
observed in DES-treated normal mice [8]. As it was
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proved, in about 70-80% endometrial carcinomas ER
is expressed [11]. The XbaI RFLP genotype XX has
been associated with a decreased risk of endometrial
cancer in a Northern European study group [43].
In one study it had been shown that the allelic vari-
ants of the ERα gene are associated with endometriosis,
adenomyosis and leiomyomata [3]. The frequency of PP
genotype was low in the patients with endometriosis,
adenomyosis and leiomyomata, whereas it was high in
the disease-free patients, suggesting that the P allele is
protective against endometriosis, adenomyosis and
leiomyomata. Similar results were reported in Greek
patients with endometriosis, who had significantly
lower frequency of PP genotype in the ERα gene com-
pared with that in the control group [48].
Although numerous studies have investigated a
possible association between ER, including ESR1
PvuII and XbaI polymorphisms and osteoporotic risk,
it remains controversial and requires further investiga-
tion. A role for the ER in the development of osteope-
nia and in skeletal growth and maintenance is exem-
plified by the case of one estrogen-resistant male
patient carrying a loss-of-function mutation in gene
encoding ERα [49]. 
Estrogens are known to be important for preserva-
tion of bone mass in females during menopause. Sev-
eral studies have shown that PP genotype has higher
bone mineral density than the Pp and pp genotypes and
Caucasian women have observed no association
between ERα gene and bone mineral density
[22,24,26,50]. These findings suggest that the local
estrogenic action is more potent in women carrying the
P allele than those carrying the p allele. This is also
supported by the finding that the PP genotype has a
higher risk of premenopausal hysterectomy and earlier
onset of natural menopause due to menorrhagia and
fibroids than the Pp and pp genotypes [30]. These find-
ings however contradict those of the studies that
showed that women carrying the PP genotype have a
lower risk for estrogen-dependent uterine disease.
Indeed, endometriotic implants and adenomyotic tis-
sues express a reduced amount of ER protein [25,51]. 
Haplotype px showed a significant association with
decreased BMD at the lumbar spine in women, while
haplotype PX was associated with increased LS-BMD
and haplotype Px did not show any association [27]. In
contrast, two other studies found the PvuII-XbaI hap-
lotype Px to be associated with decreased BMD,
whereas others showed no association [21,52,53]. In
Japanese women, the ERα PvuII PP genotype is asso-
ciated with low BMD, whereas in studies on a largely
Caucasian population from the USA or from Finland,
the PvuII pp genotype is associated with low BMD
[22,26,54].
There is a hypothesis that ESR1 polymophisms
leads to a difference in bone growth, which might be
explained by a genotype-dependent estrogen sensivity
locally at the site of bone growth. In support of this
hypothesis there is an association of ESR1 polymor-
phism with stature [36].
ERα is an isoform more highly expressed than ERβ
in mature human adipocytes and the only one
expressed in preadipocytes. ERα implication in
adipocyte growth and proliferation and - consequent-
ly- obesity development, is supported by observation
that αERKO mice possess 50-100% more adipose tis-
sue than wild-type controls, which is result of increase
in adipocyte number and size [11].
The XbaI polymorphism has been found to be sig-
nificantly associated with upper-body obesity in mid-
dle-aged persons [55]. Other observations indicated an
association between ERα intron I RFLPs and height or
body mass index [56,57]. In one study the association
of the A→G polymorphism or the combination of the
T→C and A→G polymorphisms with not only a
greater BMI, but also larger % fat mass, FM, waist cir-
cumference and WHR in middle-aged women had
been shown [55].
The ESR1 PvuII polymorphism is associated with a
higher risk of stroke in men [58]. Both ERα and ERβ
are found in various regions of the human brain,
including the hypothalamus, hippocampus, cerebral
cortex, midbrain, brainstem and forebrain, and ER-
mediated effects are thought to provide neuroprotec-
tion, with suggestion that ERα is more important in
this process [59]. The expression of ERα appears to
dominate in the hypothalamus and amygdale, suggest-
ing that this subtype is an important mediator of effects
of estrogen on emotional and reproductive behavior
[59,60]. There are suggestions based on some clinical
studies that ESR1 may influence various aspects of
personality in women and an association between ERα
polymorphism and personality traits (measured by
means of temperament and character inventory) as
well as with conduct disorder had been proved [61]. It
had been found that in women ERα haplotypes creat-
ed by the PvuII and XbaI polymorphisms increased the
likehood of having an anxiety but not of having a
depressive disorder [19]. The RFLPs for PvuII and
XbaI in intron 1 have been associated with likelihood
of developing Alzheimer's disease, again with differ-
ences in the specific allelic associations being seen
between Japanese and European subject groups
[17,18].
From clinical observations that the onset of symp-
toms of rheumatoid arthritis is often associated with
menopausal transition came the idea of role of ERα
polymorphism [62]. Indeed, there was a significant
difference between six genotype groups in female
rheumatoid arthritis age at onset [63].
ERα gene polymorphism is probably one from the
genetic factors contributing the development of clini-
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cal heterogeneity and sexually dimorphic manifesta-
tions of Lupus Nephritis, which is an autoimmune dis-
ease with high prevalence among childbearing women
and its manifestation differs in women and men. The
PpXx genotype may be associated with the suscepti-
bility of SLE in male [35].
Polymorphism of ERα (presence of PX haplotype)
in the patients genotype associates with occurrence of
acute graft-versus-host disease and lower overall sur-
vival, following the correction for known clinical and
genotypic risk features [6].
Recently, a possible relation of ERα polymor-
phisms with male infertility has been reported in Greek
and Japanese populations [64,65]. The XbaI RFLP
showed a significant association with infertility,
whereas this association was not found for the PvuII
polymorphism.
Polymorphisms in the intron 1 region of the ERα
gene are being linked to an increasing number of human
pathologies. It is unclear how the anonymous intronic
polymorphism of the ERα gene influences its protein
function. Their position in an intron near the gene pro-
moter might suggest a possible role in either transcrip-
tion regulation (ERα gene transcription can occur from
alternative promoters) or mRNA processing and stabili-
ty (numerous alternate splice variants of the primary
ERα transcript are reported in human cells).
Recently, Herrrington noted that T→C transition
associated with loss of PvuII site (P allele) results in a
potential binding site for myb transcription factors
that, in the presence of B-myb, is capable of augment-
ing in vitro transcription of a downstream reporter con-
struct tenfold [66]. Thus, in some settings, the pres-
ence of the P allele might amplify ERα transcription.
An alternative explanation is that the to polymor-
phisms in intron 1 may be in linkage disequilibrium
with causal polymorphisms elsewhere in the ERα gene
or, less likely, in an adjacent gene [14]. In this regard,
it has been well established that intron 1 polymor-
phisms are in linkage disequilibrium with the upstream
TA repeat polymorphism in the promoter region of the
ERα gene (Fig. 1) [28].
A promising and interesting field in studies of ER
gene polymorphisms comes from their possible phar-
macogenomic implications in determining the
response to hormone replacement therapy. The posi-
tive influence of postmenopausal HRT on bone mass is
well established and its antifracture effect is widely
accepted. However, it seems that there are some
women who do not respond to RT, and a possible
explanation for their less favorable responsiveness to
estrogen may be related to ER genotypes. This issue
has been investigated in a few studies performed in
different ethnic populations, with conflicting results.
There is also very interesting evidence that PvuII poly-
morphism in the ERα gene influences individual
response to HRT with regard to cholesterol levels and
other cardiovascular markers [67]. If, in the future, we
could determine women with a greater or lesser
response to HT, the treatment could be directed to
women most able to benefit from it.
In the future, studies will have to further examine
the spectrum of variation across the ESR1 gene and to
establish whether any significant association results
can be replicated both within and between ethnic
groups. The number of studied groups should be large
enough in order to test gene-gene and gene-environ-
ment interactions that may potentially be involved at
the interface of ESR1 variation and human diseases. It
would be worthwhile to conduct studies in other het-
erogeneous populations in order to assess the replica-
tion validity of present findings.
We hope that future studies will further clarify the
role of ERα in the development and progression of dif-
ferent diseases and may help to identify diagnostic or
therapeutic markers. It would allow tailoring the type
and duration of hormone therapy based on genetic pro-
file and provide a means to optimize treatment for each
patient. 
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